Home » Topics » Ocular, BioWorld Science

Ocular, BioWorld Science
RSS

ADL-2-1294 licensed to Santen for ophthalmic indications

April 28, 2000

No Comments

CPMP recommends European approval of Visudyne for wet AMD

April 19, 2000

No Comments

FDA approves Visudyne therapy for treatment of AMD

April 13, 2000

No Comments

Interferon alfa-2b offers protection from eye involvement in Behcet's disease

April 13, 2000

No Comments

New ocular antibiotic enters the pipeline at InSite Vision

April 12, 2000

No Comments

Gilead licenses NX-1838, a new AMD treatment, to EyeTech

April 10, 2000

No Comments

QLT and Ciba Vision report positive Visudyne clinical results

April 3, 2000

No Comments

Neurocrine Biosciences awarded NIH grant for retinal ischemia research

April 3, 2000

No Comments

Visudyne T-IND program expanded

March 20, 2000

No Comments

InSite Vision's batimastat eyedrops show antiangiogenic activity

March 20, 2000

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Ocular, BioWorld Science
RSS

ADL-2-1294 licensed to Santen for ophthalmic indications

CPMP recommends European approval of Visudyne for wet AMD

FDA approves Visudyne therapy for treatment of AMD

Interferon alfa-2b offers protection from eye involvement in Behcet's disease

New ocular antibiotic enters the pipeline at InSite Vision

Gilead licenses NX-1838, a new AMD treatment, to EyeTech

QLT and Ciba Vision report positive Visudyne clinical results

Neurocrine Biosciences awarded NIH grant for retinal ischemia research

Visudyne T-IND program expanded

InSite Vision's batimastat eyedrops show antiangiogenic activity

Today's news in brief

Today's news in brief

Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal

Abbvie and Simcere enter a $1B T-cell engager deal

Proteomics study explores how protein changes influence disease

Ocular, BioWorld Science RSS

Ocular, BioWorld Science
RSS